Multicenter	multicenter	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
,	,	O	O	O	O
multiple-dose	multiple-dose	O	O	O	O
,	,	O	O	O	O
parallel-groups	parallel-groups	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
safety	safety	O	O	O	O
trial	trial	O	O	O	O
of	of	O	O	O	O
azelastine	azelastine	O	O	OTHERS	I
,	,	O	O	O	O
chlorpheniramine	chlorpheniramine	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
placebo	placebo	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
spring	spring	O	O	OTHERS	I
allergic	allergic	O	O	OTHERS	I
rhinitis	rhinitis	O	O	OTHERS	I
.	.	O	O	O	O

Azelastine	azelastine	O	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
novel	novel	O	O	O	O
antiallergic	antiallergic	O	O	O	O
medication	medication	O	O	O	O
,	,	O	O	O	O
was	was	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
chlorpheniramine	chlorpheniramine	O	O	OTHERS	I
maleate	maleate	O	O	OTHERS	I
and	and	O	O	O	O
placebo	placebo	O	O	O	O
for	for	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
safety	safety	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
spring	spring	O	O	OTHERS	I
allergic	allergic	O	O	OTHERS	I
rhinitis	rhinitis	O	O	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
multicenter	multicenter	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
,	,	O	O	O	O
multiple-dose	multiple-dose	O	O	O	O
,	,	O	O	O	O
parallel-groups	parallel-groups	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

One	one	O	O	O	O
hundred	hundred	O	O	O	O
fifty-five	fifty-five	O	O	O	O
subjects	subjects	O	O	O	O
participated	participated	O	O	O	O
.	.	O	O	O	O

Subjects	subjects	O	O	O	O
ranged	ranged	O	O	O	O
in	in	O	O	O	O
age	age	O	O	O	O
from	from	O	O	O	O
18	18	O	O	O	O
to	to	O	O	O	O
60	60	O	O	O	O
years	years	O	O	O	O
of	of	O	O	O	O
age	age	O	O	O	O
and	and	O	O	O	O
had	had	O	O	O	O
at	at	O	O	O	O
least	least	O	O	O	O
a	a	O	O	O	O
2-year	2-year	O	O	O	O
history	history	O	O	O	O
of	of	O	O	O	O
spring	spring	O	O	OTHERS	I
allergic	allergic	O	O	OTHERS	I
rhinitis	rhinitis	O	O	OTHERS	I
,	,	O	O	O	O
confirmed	confirmed	O	O	O	O
by	by	O	O	O	O
positive	positive	O	O	O	O
skin	skin	O	O	O	O
test	test	O	O	O	O
to	to	O	O	O	O
spring	spring	O	O	O	O
aeroallergens	aeroallergens	O	O	O	O
.	.	O	O	O	O

Medications	medications	O	O	O	O
were	were	O	O	O	O
given	given	O	O	O	O
four	four	O	O	O	O
times	times	O	O	O	O
daily	daily	O	O	O	O
;	;	O	O	O	O
the	the	O	O	O	O
azelastine	azelastine	O	O	OTHERS	I
groups	groups	O	O	O	O
received	received	O	O	O	O
0.5	0.5	O	O	O	O
,	,	O	O	O	O
1.0	1.0	O	O	O	O
,	,	O	O	O	O
or	or	O	O	O	O
2.0	2.0	O	O	O	O
mg	mg	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
morning	morning	O	O	O	O
and	and	O	O	O	O
evening	evening	O	O	O	O
with	with	O	O	O	O
placebo	placebo	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
early	early	O	O	O	O
and	and	O	O	O	O
late	late	O	O	O	O
afternoon	afternoon	O	O	O	O
;	;	O	O	O	O
the	the	O	O	O	O
chlorpheniramine	chlorpheniramine	O	O	OTHERS	I
group	group	O	O	O	O
received	received	O	O	O	O
4.0	4.0	O	O	O	O
mg	mg	O	O	OTHERS	I
four	four	O	O	O	O
times	times	O	O	O	O
daily	daily	O	O	O	O
.	.	O	O	O	O

Daily	daily	O	O	O	O
subject	subject	O	O	O	O
symptom	symptom	O	O	O	O
cards	cards	O	O	O	O
were	were	O	O	O	O
completed	completed	O	O	O	O
during	during	O	O	O	O
a	a	O	O	O	O
screening	screening	O	O	O	O
period	period	O	O	O	O
to	to	O	O	O	O
assess	assess	O	O	O	O
pretreatment	pretreatment	O	O	O	O
symptoms	symptoms	O	O	O	O
and	and	O	O	O	O
during	during	O	O	O	O
a	a	O	O	O	O
4-week	4-week	O	O	O	O
treatment	treatment	O	O	O	O
period	period	O	O	O	O
while	while	O	O	O	O
subjects	subjects	O	O	O	O
received	received	O	O	O	O
study	study	O	O	O	O
medications	medications	O	O	O	O
.	.	O	O	O	O

Individual	individual	O	O	O	O
symptoms	symptoms	O	O	O	O
,	,	O	O	O	O
total	total	O	O	O	O
symptoms	symptoms	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
major	major	O	O	O	O
symptoms	symptoms	O	O	O	O
were	were	O	O	O	O
compared	compared	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
efficacy	efficacy	O	O	O	O
of	of	O	O	O	O
medication	medication	O	O	O	O
.	.	O	O	O	O

Elicited	elicited	O	O	O	O
,	,	O	O	O	O
volunteered	volunteered	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
observed	observed	O	O	O	O
adverse	adverse	O	O	O	O
experiences	experiences	O	O	O	O
were	were	O	O	O	O
recorded	recorded	O	O	O	O
for	for	O	O	O	O
each	each	O	O	O	O
subject	subject	O	O	O	O
and	and	O	O	O	O
compared	compared	O	O	O	O
among	among	O	O	O	O
groups	groups	O	O	O	O
.	.	O	O	O	O

Vital	vital	O	O	O	O
signs	signs	O	O	O	O
,	,	O	O	O	O
body	body	O	DISEASE	OTHERS	I
weights	weights	O	DISEASE	OTHERS	I
,	,	O	O	O	O
serum	serum	O	O	O	O
chemistry	chemistry	O	O	O	O
values	values	O	O	O	O
,	,	O	O	O	O
complete	complete	O	O	O	O
blood	blood	O	O	O	O
cell	cell	O	O	O	O
counts	counts	O	O	O	O
,	,	O	O	O	O
urine	urine	O	O	O	O
studies	studies	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
electrocardiograms	electrocardiograms	O	O	O	O
were	were	O	O	O	O
obtained	obtained	O	O	O	O
for	for	O	O	O	O
each	each	O	O	O	O
subject	subject	O	O	O	O
and	and	O	O	O	O
compared	compared	O	O	O	O
among	among	O	O	O	O
groups	groups	O	O	O	O
.	.	O	O	O	O

Symptoms	symptoms	O	O	O	O
relief	relief	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
group	group	O	O	O	O
receiving	receiving	O	O	O	O
the	the	O	O	O	O
highest	highest	O	O	O	O
concentration	concentration	O	O	O	O
of	of	O	O	O	O
azelastine	azelastine	O	O	OTHERS	I
(	(	O	O	O	O
2.0	2.0	O	O	O	O
mg	mg	O	O	OTHERS	I
twice	twice	O	O	O	O
daily	daily	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
statistically	statistically	O	O	O	O
greater	greater	O	O	O	O
than	than	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
placebo	placebo	O	O	O	O
group	group	O	O	O	O
during	during	O	O	O	O
all	all	O	O	O	O
weeks	weeks	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

Lower	lower	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
azelastine	azelastine	O	O	OTHERS	I
were	were	O	O	O	O
statistically	statistically	O	O	O	O
more	more	O	O	O	O
effective	effective	O	O	O	O
than	than	O	O	O	O
placebo	placebo	O	O	O	O
only	only	O	O	O	O
during	during	O	O	O	O
portions	portions	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
3	3	O	O	O	O
weeks	weeks	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
contrast	contrast	O	O	OTHERS	I
,	,	O	O	O	O
although	although	O	O	O	O
the	the	O	O	O	O
chlorpheniramine	chlorpheniramine	O	O	OTHERS	I
group	group	O	O	O	O
did	did	O	O	O	O
have	have	O	O	O	O
fewer	fewer	O	O	O	O
symptoms	symptoms	O	O	O	O
than	than	O	O	O	O
the	the	O	O	O	O
placebo	placebo	O	O	O	O
group	group	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
difference	difference	O	O	O	O
never	never	O	O	O	O
reached	reached	O	O	O	O
statistical	statistical	O	O	O	O
significance	significance	O	O	O	O
during	during	O	O	O	O
any	any	O	O	O	O
week	week	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
were	were	O	O	O	O
no	no	O	O	O	O
serious	serious	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
in	in	O	O	O	O
any	any	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
groups	groups	O	O	O	O
.	.	O	O	O	O

Drowsiness	drowsiness	O	O	OTHERS	I
and	and	O	O	O	O
altered	altered	O	O	OTHERS	I
taste	taste	O	O	OTHERS	I
perception	perception	O	O	OTHERS	I
were	were	O	O	O	O
increased	increased	O	O	O	O
significantly	significantly	O	O	O	O
over	over	O	O	O	O
placebo	placebo	O	O	O	O
only	only	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
high-dose	high-dose	O	O	O	O
azelastine	azelastine	O	O	OTHERS	I
group	group	O	O	O	O
.	.	O	O	O	O

Azelastine	azelastine	O	O	OTHERS	I
appears	appears	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
a	a	O	O	O	O
safe	safe	O	O	O	O
,	,	O	O	O	O
efficacious	efficacious	O	O	O	O
medication	medication	O	O	O	O
for	for	O	O	O	O
seasonal	seasonal	O	O	OTHERS	I
allergic	allergic	O	O	OTHERS	I
rhinitis	rhinitis	O	O	OTHERS	I
.	.	O	O	O	O

